infectious disease

Nestle gets closer to Seres, pledging $525m for microbiome C. diff drug

https://pharmaphorum.com/news/nestle-gets-closer-to-seres-pledging-525m-for-microbiome-c-diff-drug/

Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy

https://pharmaphorum.com/news/gilead-challenges-viiv-in-resistant-hiv-filing-twice-yearly-therapy/

Gilead preps filing for hepatitis D therapy Hepcludex in US

https://pharmaphorum.com/news/gilead-preps-filing-for-hepatitis-d-therapy-hepcludex-in-us/

https://pharmaphorum.com/events/cell-mediated-therapies-for-infectious-disease-summit/

ViiV’s Rukobia cleared in EU as rescue HIV therapy

https://pharmaphorum.com/news/viivs-rukobia-cleared-in-eu-as-rescue-hiv-therapy/

EUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failed

https://pharmaphorum.com/news/eusa-pharma-hopes-il-6-drug-will-work-in-covid-19-where-class-rivals-failed/

Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir

https://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/

Adult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13

https://pharmaphorum.com/news/adult-data-back-mercks-challenger-to-pfizers-blockbuster-prevnar-13/

Scynexis bids to end novel antifungal drought, filing ibrexafungerp in US

https://pharmaphorum.com/news/scynexis-bids-to-end-novel-antifungal-drought/

1 2 3 4 5

Close in 10 seconds

Pharmaphorum.com

Search